touchPODCAST

The potential of BTKi therapies in delaying MS progression

touchEXPERT FOCUS for touchNEUROLOGY

Join Prof. Montalban as he shares expert insights into the pathophysiology of progressive MS and the rationale for targeting BTK inhibitors. He reviews emerging clinical data supporting the use of BTK inhibitors and discusses how they may fit into the evolving treatment landscape. In this context, Prof. Montalban also considers current guideline-recommended therapies for progressive MS and highlights key areas of remaining unmet treatment need.

The expert

Prof. Xavier Montalban, Centre d'Esclerosi Múltiple de Catalunya (Cemcat) and Vall d'Hebron University Hospital, Barcelona, Spain

This touchPODCAST is for HCPs outside of the UK only.

This activity is provided by an independent medical education grant from Sanofi. 

The activity is jointly provided by USF Health and touchIME. 

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchneurology.com/ 

Reducing burden of disease in gMG: Exploring the role of FcRn inhibitors

touchPANEL DISCUSSION for touchNEUROLOGY

Listen to two expert neurologists and a neurology nurse as they explore the role of neonatal Fc receptor (FcRn) inhibitors in improving the burden of disease in patients with generalized myasthenia gravis. The faculty will consider how the burden of disease and treatment in patients with generalized myasthenia gravis can be used to inform treatment decisions, the latest clinical data for FcRn inhibitors and the best practice strategies for using FcRn inhibitors in clinical practice. 

The experts

• Prof. Michael Nicolle – Western University and London Health Sciences Centre, London, ON, Canada
• Dr Karissa Gable – Duke University, Durham, NC, USA
• Ms Missy Pittman – Duke University, Durham, NC, USA

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from Argenx and UCB, Inc. 

The activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchneurologyime.org/reducing-burden-of-disease-in-gmg-exploring-the-role-of-fcrn-inhibitors/

 

MDT perspectives on why and how to implement continuous glucose monitoring in T2D

Listen to key experts from a multidisciplinary team review and discuss why and how to implement continuous glucose monitoring in T2D.

The multidisciplinary team

• Endocrinologist: Prof Tina Vilsbøll
• Primary Care Physician: Dr Gihane Zarifa
• Nurse specialist: Ms. Lori Berard
• Patient advocate: Mr. Ostap Soroka

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Novo Nordisk. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

 

For further information visit our website: https://touchendocrinologyime.org/mdt-empowering-t2d-management-the-evolution-of-basal-insulin-therapy/

 

 

MDT perspectives on evolving options for insulin therapy

Listen to key experts from a multidisciplinary team review and discuss evolving options for insulin therapy. 

The multidisciplinary team

• Endocrinologist: Prof Tina Vilsbøll
• Primary Care Physician: Dr Gihane Zarifa

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Novo Nordisk. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchendocrinologyime.org/mdt-empowering-t2d-management-the-evolution-of-basal-insulin-therapy/

 

 

MDT perspectives on understanding clinical inertia in T2D

Listen to key experts from a multidisciplinary team review and discuss clinical inertia in T2D.

The multidisciplinary team

• Endocrinologist: Prof Tina Vilsbøll
• Primary Care Physician: Dr Gihane Zarifa
• Patient advocate: Mr. Ostap Soroka

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Novo Nordisk. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchendocrinologyime.org/mdt-empowering-t2d-management-the-evolution-of-basal-insulin-therapy/

 

Navigating the clinical impact of TROP2-targeting in NSCLC

touchSYMPOSIUM for touchRESPIRATORY

Listen to this touchSYMPOSIUM recorded live in March 2025 at the The European Lung Cancer Congress in Paris, France.

Symposium chair Prof. Marina Garassino is joined by Prof. Jarushka Naidoo and Prof. David Planchard to explore the evolving role of TROP2-targeted ADCs in NSCLC. 

Session 1: Prof. Marina Garassino highlights the emergence of TROP2 in NSCLC as a promising area of therapeutic innovation

Session 2: Prof.  Jaruska Naidoo discusses the latest clinical trial findings for TROP2-targeting ADCs in NSCLC

Session 3: Prof. David Planchard discusses the complexities of using TROP2 as a biomarker for patient selection

Session 4: A panel discussion offering practical approaches for managing adverse effects associated with TROP2-targeted ADCs in clinical practice, with Q&A.

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Daiichi Sankyo and AstraZeneca and is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/

Navigating the clinical impact of TROP2-targeting in NSCLC

touchSYMPOSIUM for touchONCOLOGY

Listen to this touchSYMPOSIUM recorded live in March 2025 at the The European Lung Cancer Congress in Paris, France.

Symposium chair Prof. Marina Garassino is joined by Prof. Jarushka Naidoo and Prof. David Planchard to explore the evolving role of TROP2-targeted ADCs in NSCLC. 

Session 1: Prof. Marina Garassino highlights the emergence of TROP2 in NSCLC as a promising area of therapeutic innovation

Session 2: Prof.  Jaruska Naidoo discusses the latest clinical trial findings for TROP2-targeting ADCs in NSCLC

Session 3: Prof. David Planchard discusses the complexities of using TROP2 as a biomarker for patient selection

Session 4: A panel discussion offering practical approaches for managing adverse effects associated with TROP2-targeted ADCs in clinical practice, with Q&A.

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Daiichi Sankyo and AstraZeneca and is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/

Integrating treatment advances for alpha-mannosidosis into effective MDT care - touchNEUROLOGY

touchPANEL DISCUSSION for touchNEUROLOGY

Listen to a panel of world-leading experts in lysosomal storage disorders  explore treatment needs along the lifespan of people living with alpha-mannosidosis, discuss the evolving treatment landscape, and finally, reflect on how treatment advances may be integrated into the multidisciplinary management of alpha-mannosidosis, with the aim of optimizing patient outcomes.

The experts

• Dr Barbara K. Burton, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
• Dr Can Ficicioglu, Children's Hospital of Philadelphia, PA, USA
• Dr Christina Lampe, University of Giessen, Giessen, Germany

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Chiesi USA, Inc. 

The activity is jointly provided by USF Health and touchIME. 

For further information visit: touchneurologyime.org/

Integrating treatment advances for alpha-mannosidosis into effective MDT care - touchENDOCRINOLOGY

touchPANEL DISCUSSION for touchENDOCRINOLOGY

Listen to a panel of world-leading experts in lysosomal storage disorders  explore treatment needs along the lifespan of people living with alpha-mannosidosis, discuss the evolving treatment landscape, and finally, reflect on how treatment advances may be integrated into the multidisciplinary management of alpha-mannosidosis, with the aim of optimizing patient outcomes.

The experts

• Dr Barbara K. Burton, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
• Dr Can Ficicioglu, Children's Hospital of Philadelphia, PA, USA
• Dr Christina Lampe, University of Giessen, Giessen, Germany

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Chiesi USA, Inc. 

The activity is jointly provided by USF Health and touchIME. 

For further information visit: touchendocrinologyime.org/

The evolving standard of care for advanced/recurrent endometrial cancer: A practice-focused discussion of immunotherapy

touchIN CONVERSATION for touchONCOLOGY

Listen to two expert gynaecologic oncology specialists discuss the evolving role of immunotherapy in the treatment of advanced/recurrent endometrial cancer. They explore how immune checkpoint inhibitors are reshaping standards of care across lines of therapy, highlight key practical considerations for optimizing patient selection and management, and examine emerging data that may influence future treatment paradigms.

The experts

• Dr Alexandra Leary, Gustave Roussy Cancer Center, Villejuif, France
• Dr Juan Francisco Grau, Gustave Roussy Cancer Center, Villejuif, France

This touchPODCAST is for HCPs outside of the USA and UK only. 

This activity is funded by an independent medical education grant from GSK.

This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/